Good morning mooers! Here are things you need to know about today's Singapore:
●Singapore shares opened lower on Monday; STI down 1.01%
●Commodities face tough week as Fed angst builds
●Stocks and REITs to watch: Singtel, SPH Reit, Aspen
●Latest share buy back transactions
-moomoo News SG
Market Trend
Singapore shares opened lower on Monday. The $FTSE Singapore Straits Time Index (.STI.SG)$ decreased 1.01 per cent to 3,114.16 ...

$Pfizer (PFE.US)$ Pfizer will provide an additional 2.5 million courses of oral COVID-19 drug Paxlovid to the UK. Pfizer said it expects 2.75 million courses of Paxlovid to be delivered to the UK by 2022. Last month, Pfizer said it planned to seek approval for Paxlovid in Europe. In addition, the United States will purchase 10 million doses of Paxlovid for $5.3 billion.

$Pfizer (PFE.US)$ Analyst Louise Chen said that on Pfizer's upcoming investor day, the company's new crown vaccine and new crown oral drug Paxlovid will be the focus of attention. If the company’s management can guarantee the durability of vaccine sales and the peak sales potential of oral drugs, this may be a positive catalyst.
According to analysts, her peak sales potential for these two businesses is estimated to be between US$50 billion and US$60 billion. She pointed out that the rising number of new crown infections and concerns about the Ome Keron variant, and the weakened effectiveness of the existing new crown vaccine against the Ome Keron variant, can support her view; although there are other pharmaceutical companies in the Research on next-generation antibodies, but it may not be available until later in 2022.
Article excerpted from the US Stock Research Agency

$Pfizer (PFE.US)$ I don't understand why vaccine stocks would experience such a steep plunge?

$Pfizer (PFE.US)$ rocket

$Pfizer (PFE.US)$ In theory, it shouldn't be like this. Take another look.